AU2003295561A1 - Inhibitory oliogonucleotides targeted to bcl-2 - Google Patents

Inhibitory oliogonucleotides targeted to bcl-2 Download PDF

Info

Publication number
AU2003295561A1
AU2003295561A1 AU2003295561A AU2003295561A AU2003295561A1 AU 2003295561 A1 AU2003295561 A1 AU 2003295561A1 AU 2003295561 A AU2003295561 A AU 2003295561A AU 2003295561 A AU2003295561 A AU 2003295561A AU 2003295561 A1 AU2003295561 A1 AU 2003295561A1
Authority
AU
Australia
Prior art keywords
seq
oligonucleotide
oligonucleotides
bcl
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003295561A
Other languages
English (en)
Inventor
Zhidong Chen
Richard Koehn
Ramesh Prakash
Duane E. Ruffner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Salus LLC
Original Assignee
Genta Salus LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Salus LLC filed Critical Genta Salus LLC
Publication of AU2003295561A1 publication Critical patent/AU2003295561A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AU2003295561A 2002-11-14 2003-11-14 Inhibitory oliogonucleotides targeted to bcl-2 Abandoned AU2003295561A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42626902P 2002-11-14 2002-11-14
US60/426,269 2002-11-14
PCT/US2003/036614 WO2004046327A2 (en) 2002-11-14 2003-11-14 Inhibitory oliogonucleotides targeted to bcl-2

Publications (1)

Publication Number Publication Date
AU2003295561A1 true AU2003295561A1 (en) 2004-06-15

Family

ID=32326325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295561A Abandoned AU2003295561A1 (en) 2002-11-14 2003-11-14 Inhibitory oliogonucleotides targeted to bcl-2

Country Status (6)

Country Link
US (2) US7256284B2 (cg-RX-API-DMAC7.html)
EP (1) EP1572970A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006514546A (cg-RX-API-DMAC7.html)
AU (1) AU2003295561A1 (cg-RX-API-DMAC7.html)
CA (1) CA2505680A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004046327A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20050287667A1 (en) * 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
JP5122474B2 (ja) 2005-12-01 2013-01-16 プロネイ・セラピューティクス・インコーポレイテッド 両性リポソーム製剤
WO2009071681A2 (en) * 2007-12-07 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of bcl-2
EP2350296A4 (en) * 2008-11-17 2013-04-03 Enzon Pharmaceuticals Inc BRANCHED CATIONIC LIPIDS FOR THE SYSTEM FOR INTRODUCING NUCLEIC ACIDS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5912147A (en) * 1996-10-22 1999-06-15 Health Research, Inc. Rapid means of quantitating genomic instability
US6041181A (en) * 1997-07-23 2000-03-21 International Business Machines Corporation Method of, system for, and computer program product for providing quick fusion in WHERE constructs
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
DE69938128D1 (de) * 1998-03-28 2008-03-27 Univ Utah Res Found Zielgerichtete antisense-bibliotheken
KR20020013519A (ko) * 1999-04-08 2002-02-20 추후제출 보편적 및/또는 축퇴성 염기를 포함하는 안티센스올리고뉴클레오티드
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
US7056653B2 (en) * 2000-02-10 2006-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Detection of binding of charged species using PH- or potential-sensitive probes
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7060690B2 (en) * 2001-01-22 2006-06-13 Genta Incorporated Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof

Also Published As

Publication number Publication date
US7256284B2 (en) 2007-08-14
JP2006514546A (ja) 2006-05-11
WO2004046327A2 (en) 2004-06-03
EP1572970A2 (en) 2005-09-14
WO2004046327A3 (en) 2005-12-29
CA2505680A1 (en) 2004-06-03
EP1572970A4 (en) 2006-11-15
US20040152654A1 (en) 2004-08-05
US20080096835A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
US20240360452A1 (en) Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53
EP2850186B1 (en) Compositions and methods for modulating smn gene family expression
EP3400948B1 (en) Methods and means for efficient skipping of at least exon 52 of the human duchenne muscular dystrophy gene
US20150247145A1 (en) Methods for modulating rna using 3' targeting oligonucleotides
WO2023171820A1 (ja) キャリアペプチドが連結された核酸
EA038478B1 (ru) Композиции и способы для ингибирования генной экспрессии лпа
KR20110017005A (ko) Tgf-베타 수용체 유전자 발현 억제용 조성물 및 방법
JP7634542B2 (ja) B型肝炎ウイルス感染症を処置するためのsept9阻害剤の使用
US20230118138A1 (en) Use of scamp3 inhibitors for treating hepatitis b virus infection
US20080096835A1 (en) Inhibitory oligonucleotides targeted to BCL-2
US20240294907A1 (en) Selective delivery of oligonucleotides to glial cells
JP2025094072A (ja) B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用
WO2021122993A1 (en) Use of saraf inhibitors for treating hepatitis b virus infection
WO2004035759A2 (en) Inhibitory oligonucleotides targeted to matrix metalloproteinase-9
WO2025254047A1 (ja) アンドロゲン受容体 rna配列に基づく新規二本鎖rna及びその利用
WO2026048822A1 (ja) Mapt rna配列に基づく新規二本鎖rna及びその利用
WO2025103457A1 (zh) 抑制LPA表达的siRNA及其用途
HK40071185A (en) Use of sept9 inhibitors for treating hepatitis b virus infection
CN122070363A (zh) 靶向转甲状腺素蛋白的寡核苷酸及其用途
BR112018006489B1 (pt) Agente de interferência de rna (rnai) da lipoproteína a (lpa), seus usos e composição farmacêutica
HK1262582B (en) Methods and means for efficient skipping of at least exon 52 of the human duchenne muscular dystrophy gene

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application